Endeavor Drug-Eluting Stent Now with Rapid Exchange Delivery System

The Endeavor Sprint drug-eluting stent (DES) incorporates a new low profile tip design, a new balloon material, as well as an enhanced shaft design, which together improve the device's deliverability. The Endeavor DES is made of an advanced cobalt alloy, with a modular, low crossing profile design, which makes it more flexible, helping the physician navigate tortuous anatomy. A nonthrombogenic and noninflammatory biocompatible polymer coating that mimics red blood cell chemistry is used to bind and then release Zotarolimus, a potent antiproliferative lipophilic drug that elutes completely from the stent and maintains effective tissue concentration through 28 days. The addition of a rapid exchange (RX) delivery system--a short-, single-wire delivery system that can be used by one operator--makes the delivery of the DES to the site of coronary intervention even easier. The Endeavor Sprint DES and the RX delivery system are products of Medtronic (Minneapolis, MN, USA).
.
"The Endeavor Sprint system takes deliverability to a new level,” said Professor Ian Meredith of Monash Medical Center (Melbourne, Australia). "It features a balloon catheter designed specifically for the stent it delivers. Combining it with RX, the Endeavor Sprint system further enhances the deliverability of the Endeavor DES, which already had high marks on this aspect of procedural success, even in challenging lesions.”

"The Endeavor Sprint drug-eluting stent system is the latest innovation to come out of our robust product pipeline in CardioVascular,” said Sean Salmon, vice president and general manager of the coronary and peripheral vascular business at Medtronic. "It represents the strong and ongoing commitment we have to the field of interventional cardiovascular therapeutics. That commitment will yield many more collaborative innovations in the future that fulfill the unmet medical needs of patients worldwide.”

Related Links:
Medtronic
Monash Medical Center